AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.
Agricola
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.
American Journal of Clinical Nutrition, Vol. 71, No. 3, 701-705, March 2000
© 2000 American Society for Clinical Nutrition


Original Research Communications

Dietary medium-chain triacylglycerol prevents the postprandial rise of plasma triacylglycerols but induces hypercholesterolemia in primary hypertriglyceridemic subjects1,2,3

Leiko Asakura, Ana MP Lottenberg, Mônica QTS Neves, Valéria S Nunes, Jussara C Rocha, Marisa Passarelli, Edna R Nakandakare and Eder CR Quintão

1 From the Lipids Laboratory (LIM 10), University of São Paulo Medical School, São Paulo, Brazil.

2 Corn oil provided by Refinações de Milho Brasil Ltda, São Paulo, Brazil; medium-chain triacylglycerol provided by Nutricia Produtos Dietéticos e Nutricionais SA, São Paulo, Brazil; skim milk provided by Nestlé Indústria e Comércio Ltda, São Paulo, Brazil; and lyophilized mixture provided by Liotécnica Indústria e Comércio Ltda, Laboratórios de Investigação Médica (LIM), Hospital das Clínicas, São Paulo, Brazil.

3 Address correspondence to ECR Quintão, Faculdade de Medicina da Universidade de São Paulo, Av Dr Arnaldo, 455, sala 3317, LIM 10, CEP 01246-903, São Paulo SP, Brazil. E-mail: lipideq{at}usp.br.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Previous studies showed divergent results concerning the influence of medium-chain triacylglycerol (MCT) on lipoprotein metabolism.

Objective: The objective of this study was to compare the effects of MCT and corn oil on plasma lipids in primary hypertriglyceridemic patients.

Design: Ten subjects ate different proportions of corn oil and MCT for 12 wk. The subjects first ate a low-fat diet for 2 wk and during the next 4 wk, corn oil was added as the sole source of fat. Thereafter, for 2-wk periods, the subjects were sequentially fed corn oil and MCT mixed in the following proportions: 3:1, 1:1, and 0:1. Fasting plasma total cholesterol, triacylglycerol, and HDL-cholesterol concentrations were measured at the end of each period. At the end of the 100%–corn oil and of the 100%-MCT periods, subjects were fed a test meal containing the respective oil (40 g fat/m2 body surface area) and total cholesterol and triacylglycerols were measured at 2-h intervals over 8 h; fasting lipoprotein composition was also measured.

Results: Compared with corn oil, MCT was associated with a higher mean (±SD) fasting total cholesterol concentration (6.39 ± 1.14 compared with 5.51 ± 0.98 mmol/L, respectively; P < 0.05); non-HDL-cholesterol concentrations were also higher with MCT (5.36 ± 1.11 mmol/L) than with corn oil (4.51 ± 0.92 mmol/L; P < 0.005). In response to the liquid test meal, plasma total cholesterol did not change with either diet but triacylglycerols increased with the 100%–corn oil diet.

Conclusions: MCT prevents the risk of pancreatitis due to postprandial hypertriglyceridemia but has the inconvenience of raising total cholesterol concentrations in primary hypertriglyceridemic subjects.

Key Words: Medium-chain triacylglycerol • corn oil • hypertriglyceridemia • hypercholesterolemia • lipoprotein metabolism • test meal • nonobese adults


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Medium-chain triacylglycerol (MCT) has been used for {approx}50 y in the treatment of disorders of lipid absorption due to pancreatic lipase deficiency and as a source of energy in enteral and parenteral nutrition (1). MCT contains mainly 8–10-carbon fatty acids that facilitate the action of the pancreatic lipase, and large amounts of MCT are absorbed as triacylglycerols in patients deficient in pancreatic lipase (1). Hydrolysis of MCT to its component fatty acids is faster and more efficient than that of long-chain triacylglycerol (LCT), and the medium-chain fatty acids (MCFAs) bound to albumin reach the liver by the portal system without being incorporated into chylomicrons (1, 2). However, other studies showed that, in the liver, MCFAs may be reesterified to triacylglycerols after elongation of the carbon chain (3, 4) instead of being completely oxidized to ketone bodies (1, 2, 5).

In contrast, LCT must be hydrolyzed by pancreatic lipase and, after intestinal absorption, long-chain fatty acids (LCFAs) are reesterified to triacylglycerols, packaged as chylomicrons, and transported out of the cells into the lymphatic system (6). Several studies were conducted on the influence of MCT on serum lipid and lipoprotein metabolism, but some results are divergent. One study in healthy subjects showed that, compared with LCT, MCT produces significantly higher plasma concentrations of triacylglycerols without modifying total cholesterol (7) but that the opposite occurs when MCT is compared with myristic and oleic acids (8). MCT also resulted in a significantly greater frequency of cholesterolemia in mildly hypercholesterolemic men than did a high oleic acid sunflower oil feeding (9).

In healthy subjects, plasma total cholesterol concentrations with an MCT-supplemented diet were higher than with a corn oil–supplemented diet but lower than with a butter-enriched diet (10). Compared with safflower and coconut oils, MCT produced higher triacylglycerol concentrations in patients with diabetes and in obese patients (11) and in overfed, healthy, nonobese males (12). Several reviews were published on the physiology of MCT and on its clinical nutritional use (1, 2, 5, 13), but, except for in patients with lipoprotein lipase deficiency (14, 15), no studies are available on hypertriglyceridemic subjects in general, although they are likely to also benefit from MCT in the diet. The objective of the present investigation in primary hypertriglyceridemic patients was to compare the effects on fasting and postprandial plasma lipids and lipoproteins of a stepwise rise in the proportion of MCT in the diet.


    SUBJECTS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Subjects
Ten nonobese, adult outpatients (6 women and 4 men) with plasma triacylglycerol concentrations between 2.82 mmol/L (250 mg/dL) and 11.29 mmol/L (1000 mg/dL) were recruited at the Hospital of the University of São Paulo Medical School and enrolled in a dietary protocol. None of the subjects had diabetes, renal or hepatic diseases, or other secondary causes of hyperlipidemia or had been taking medications that interfere with lipid metabolism for >=2 mo before admission to the study. The subjects were aged between 34 and 68 y. All subjects gave their written, informed consent to participation in the study, which was approved by the Ethical Committee of the Hospital of the University of São Paulo Medical School.

Dietary protocol
All subjects consumed ad libitum their daily diet with added corn oil (Refinações de Milho Brasil Ltda, SP, São Paulo, Brazil), MCT (Unichema International, Barcelona, Spain), or both. The oils were given to the patients once a week in 500-mL bottles and the amounts not consumed were measured. The fatty acid composition of each oil as stated by the suppliers is shown in Table 1Go. The 12-wk study protocol included 5 study periods. All subjects first consumed a low-fat diet in which intrinsic fat accounted for 10.5 ± 4.6% ( ± SD) of total energy intake for 2 wk. Thereafter they received additional corn oil as the sole visible source of fat in their diet for 4 wk. In the ensuing 3 periods, each lasting 2 wk, all subjects were sequentially given mixtures of oil with the following ratios of corn oil to MCT: 3:1, 1:1, and 0:1. Throughout the study, all subjects were instructed to avoid alcoholic beverages, to consume very-low-fat foods, and to eat the added oil ad libitum.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Fatty acid composition of oils added to the diet1
 
All subjects were regularly asked about their dietary habits and fat tolerance, and a 24-h food record was obtained once during the period in which the oils were consumed in a 1:1 ratio for the purpose of evaluating the subjects' total energy intake and energy intake from fat. At the end of the 100%–corn oil and of the 100%-MCT periods, the subjects consumed a test meal that provided 40 g fat/m2 body surface area; this meal consisted of a lyophilized mixture (percentage by weight) containing 20% protein (lactoalbumin, from skim milk; Nestlé Industry, São Paulo, Brazil), 55% carbohydrate (sucrose), and 25% of the oil (corn oil or MCT) that had been eaten during the respective period. The purpose of the test meal was to measure postprandial lipid variation after an acute fat load. The mixture was prepared by adding hot water and was consumed over a 10-min period. During the test meals the subjects were allowed water ad libitum.

Lipid and lipoprotein analyses
On the first day of the initial diet period, fasting blood samples were collected in EDTA-coated tubes for lipid analyses. Thereafter, blood samples were drawn twice in the low-fat, 100%–corn oil, and 100%-MCT diet periods and once in the periods during which 75% corn oil plus 25% MCT and 50% corn oil plus 50% MCT were fed, and fresh samples and samples stored at –70°C were analyzed. Plasma total cholesterol and triacylglycerol concentrations were measured by enzymatic assays with commercially available kits (Boehringer Mannheim, Darmstadt, Germany, and Merck KgaA, Buenos Aires, respectively) using Cobas Mira software (version 8847; F Hoffmann-La Roche, Basel, Switzerland). HDL cholesterol was measured after precipitation of apolipoprotein B–containing lipoproteins with magnesium chloride and dextran sulfate (16) and non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol.

Before each test meal, blood samples were drawn on ice into tubes containing 10% EDTA (10 mL/L blood). Plasma was immediately obtained by centrifugation at 1000 x g for 10 min at 4°C in a refrigerated centrifuge (RT 6000B; Sorvall, Newton, CT) and the following preservatives were added per L: 2 mmol benzamidine/L (5 mL), 0.5% gentamycin and 0.25% chloramphenicol (20 mL), 0.87 g phenyl-methyl-sulfonyl-fluoride/L DMSO (0.5 mL), and 10 g aprotinin/L (5 mL). Plasma was then separated by discontinuous gradient density ultracentrifugation (286000 x g for 24 h at 4°C; L7–55 ultracentrifuge; Beckman, Palo Alto, CA) into fractions at the following densities (g/L): 1006 to obtain VLDL cholesterol, 1020 for intermediate-density (IDL) cholesterol, 1065 for LDL cholesterol, and 1210 for total HDL cholesterol. Lipoprotein fractions were then frozen at -70°C for further measurements of their contents of total cholesterol, triacylglycerols, total protein, and phospholipid; HDL apolipoprotein A-I content was measured by the immunoturbidimetric method using a commercial kit (Unimate 3 APOA; F Hoffmann-La Roche). Blood samples were drawn after the liquid test meal at 2-h intervals over 8 h for measurements of total cholesterol and triacylglycerol concentrations.

Statistical analyses
Fasting and postprandial cholesterolemia and triglyceridemia, patients' weights, and amounts of oils consumed were analyzed with the Friedman test and Dunn's multiple comparison test as a posttest to compare all pairs if P < 0.05. Analyses were performed with GRAPHPAD, version 2.01, for WINDOWS (Graphpad, San Diego, CA). Non-HDL-cholesterol concentrations with the 100%–corn oil and 100%-MCT diets were analyzed with the Wilcoxon signed-rank test. Differences were considered significant at P < 0.05. Postprandial cholesterolemia and triglyceridemia were quantified along time as area under the concentration-versus-time curve above a line drawn through the fasting plasma concentrations.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Clinical characteristics of the subjects (6 women and 4 men aged 49 ± 12 y) and plasma analyses are shown in Table 2Go. The subjects' body weight did not change significantly throughout the study period. In the low-fat-diet period, intrinsic fat accounted for 10.7 ± 4.6% of total energy intake. The 24-h food record showed that total fat (intrinsic plus added) accounted for 21.7 ± 6.3% of total energy intake and that added oil alone accounted for 64% of energy from fat. Added dietary oils were well tolerated and the amounts consumed did not significantly differ during the study. Fasting HDL-cholesterol and triacylglycerol concentrations did not vary significantly during the low-fat and modified-fat diet periods; thus, fasting triglyceridemia was not significantly modified by the increase in the percentage of MCT. When the subjects consumed the test meal at the end of either the 100%–corn oil or the 100%-MCT diet period, fasting total cholesterol was significantly higher (16%) with the 100%-MCT diet than with the 100%–corn oil diet and remained significantly higher during the fat absorption phase, although fat absorption by itself did not influence the concentration of plasma total cholesterol (Figure 1Go). Also, no changes occurred in the other diet periods when the ratio of corn oil to MCT varied. Fasting plasma triacylglycerol concentrations were not significantly different between the MCT and corn oil diets; however, as shown in Figure 2Go, during the fat absorption phase, plasma triacylglycerol concentrations increased with the corn oil but not with the MCT test meal.


View this table:
[in this window]
[in a new window]
 
TABLE 2. Body weights of subjects and results of plasma analyses at the end of each diet period1
 


View larger version (10K):
[in this window]
[in a new window]
 
FIGURE 1. Mean (±SD) plasma concentration of total cholesterol after consumption of liquid meals that provided 40 g fat/m2 body surface area. The fat in the test meals consisted of either corn oil ({blacksquare}) or medium-chain triacylglycerol ({square}). Areas under concentration-versus-time curve: corn oil, 1.81 ± 0.75 mmol•h/L; MCT, 1.42 ± 1.01 mmol•h/L, Wilcoxon signed-rank test, NS).

 


View larger version (11K):
[in this window]
[in a new window]
 
FIGURE 2. Mean (±SD) plasma concentration of triacylglycerol after consumption of liquid meals that provided 40 g fat/m2 body surface area. The fat in the test meals consisted of either corn oil ({blacksquare}) or medium-chain triacylglycerol ({square}). Areas under the concentration-versus-time curve: corn oil, 17.94 ± 9.64 mmol • h/L; MCT, 5.02 ± 0.87 mmol•h/L. Significant difference between MCT and corn oil for entire study period, P < 0.005 (Wilcoxon signed-rank test).

 
Lipoprotein composition analysis (Table 3Go) showed that, during the fasting state, the 100%-MCT diet produced a lower fraction of HDL cholesterol but higher fractions of the other lipoproteins (VLDL, IDL, and LDL cholesterol) than did the 100%–corn oil diet, a result that agrees with the data obtained in whole plasma. The 100%-MCT diet also produced higher triacylglycerol concentrations in IDL- and LDL-cholesterol fractions than did the 100%–corn oil diet.


View this table:
[in this window]
[in a new window]
 
TABLE 3. Results of plasma analyses at the end of the 100%–corn oil period and at the end of the 100%–medium-chain triacylglycerol (MCT) period1
 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Some studies showed variations in plasma lipids and lipoproteins when MCT was fed to normolipidemic (7, 8) and mildly hypercholesterolemic (9) subjects. However, there are no data on the effects of MCT in hypertriglyceridemic patients, except for the beneficial effects of MCT on the severe hypertriglyceridemia of lipoprotein-lipase-deficient patients. Our study was designed to alter the ratio of corn oil to MCT in the diet gradually because abrupt changes in the types and amounts of fat eaten transiently alter plasma lipid and lipoprotein concentrations (7, 9, 10, 17). All subjects maintained their body weights throughout the investigation. Although the oils were eaten ad libitum, their intake was not significantly modified during any dietary period and accounted for 12.5 ± 1.7% of total energy intake. MCT had the undesirable effect of increasing plasma fasting total cholesterol and non-HDL-cholesterol concentrations, as shown by both the lipoprotein precipitation method and discontinuous gradient density ultracentrifugation. Although the mechanism by which MCT raised plasma total cholesterol is not known, it is likely that the higher proportion of saturated fatty acids in MCT (Table 1Go) might play a role, together MCFAs, which may undergo elongation in the liver (3, 4) and thus increase the rate of VLDL-cholesterol production.

Fasting plasma triacylglycerol concentrations were not significantly altered by consumption of MCT or corn oil. As expected, postprandial total cholesterol was not influenced by the acute fat load of each test meal. However, postprandial triacylglycerol concentrations, which indicate the extent of the increase in plasma triacylglycerols above fasting values after the meal, were significantly lower with MCT than with corn oil, which might be attributable either to less chylomicron and VLDL-cholesterol formation or to the enhancement of the triacylglycerol-rich lipoprotein clearance rate in hypertriglyceridemic subjects (18, 19). Thus, MCT is useful because it potentially prevents the risk of pancreatitis due to postprandial hypertriglyceridemia; however, in the long run, an MCT-associated increase in atherogenic non-HDL-cholesterol concentrations is a major inconvenience.


    ACKNOWLEDGMENTS
 
We thank the patients who volunteered to participate in the study.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr 1982;36:950–62.[Abstract/Free Full Text]
  2. Bach AC, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy. J Lipid Res 1996;37:708–26.[Abstract]
  3. Carnielli VP, Sulkers EJ, Moretti C, et al. Conversion of octanoic acid into long-chain saturated fatty acids in premature infants fed a formula containing medium-chain triglycerides. Metabolism 1994; 43:1287–92.[Medline]
  4. Swift LL, Hill JO, Peters JC, Greene HL. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans. Am J Clin Nutr 1990;52:834–6.[Abstract/Free Full Text]
  5. Greenberger NJ, Skillman TG. Medium-chain triglycerides—physiologic considerations and clinical implications. N Engl J Med 1969;280:1045–58.
  6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432–7.[Medline]
  7. Swift LL, Hill JO, Peters JC, Greene HL. Plasma lipids and lipoproteins during 6 d of maintenance feeding with long-chain, medium-chain, and mixed-chain triglycerides. Am J Clin Nutr 1992;56:881–6.[Abstract/Free Full Text]
  8. Temme EHM, Mensink RP, Hornstra G. Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects. J Lipid Res 1997;38:1746–54.[Abstract]
  9. Cater NB, Heller HJ, Denke MA. Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans. Am J Clin Nutr 1997;65:41–5.[Abstract/Free Full Text]
  10. Hashim SA, Arteaga A, Van Itallie TB. Effect of a saturated medium-chain triglyceride on serum-lipids in man. Lancet 1960;1:1105–8.
  11. Uzawa H, Schlierf G, Chirman S, et al. Hyperglyceridemia resulting from intake of medium chain triglycerides. Am J Clin Nutr 1964; 15:365–9.[Abstract]
  12. Hill JO, Peters JC, Swift L, et al. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. J Lipid Res 1990;31:407–16.[Abstract]
  13. Bell SJ, Bradley D, Forse RA, Bistrian BR. The new dietary fats in health and disease. J Am Diet Assoc 1997;97:280–6.[Medline]
  14. Rouis M, Dugi A, Previato L, et al. Therapeutic response to medium-chain triglycerides and {omega}-3 fatty acids in a patient with familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol 1997;17:1400–6.[Abstract/Free Full Text]
  15. Shirai K, Kobayashi J, Inadera H, et al. Type I hyperlipoproteinemia caused by lipoprotein lipase defect in lipid-interface recognition was relieved by administration of medium-chain triglyceride. Metabolism 1992;41:1161–4.[Medline]
  16. Bachorik PS, Albers S. Precipitation methods for quantification of lipoproteins. Methods Enzymol 1986;129:78–100.[Medline]
  17. Ulmann D, Connor WE, Hatcher LF, Connor S, Flavell D. Will a high-carbohydrate, low fat diet lower plasma lipids and lipoproteins without producing hypertriglyceridemia? Arterioscler Thromb 1991;11:1059–67.[Abstract/Free Full Text]
  18. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of trilglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993;91:748–58.
  19. O'Meara NM, Lewis GF, Cabana VG, Iverius PH, Getz GS, Polonsky KS. Role of basal triglyceride and high-density lipoprotein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab 1992;75:465–71.[Abstract]
Received for publication January 15, 1999. Accepted for publication August 23, 1999.




This article has been cited by other articles:


Home page
J. Am. Coll. Nutr.Home page
M.-P. St-Onge, A. Bosarge, L. L. T. Goree, and B. Darnell
Medium Chain Triglyceride Oil Consumption as Part of a Weight Loss Diet Does Not Lead to an Adverse Metabolic Profile When Compared to Olive Oil
J. Am. Coll. Nutr., October 1, 2008; 27(5): 547 - 552.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
T. R. Thomas, K. E. Horner, M. M. Langdon, J. Q. Zhang, E. S. Krul, G. Y. Sun, and R. H. Cox
Effect of exercise and medium-chain fatty acids on postprandial lipemia
J Appl Physiol, April 1, 2001; 90(4): 1239 - 1246.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
K. Hayes
Medium-chain triacylglycerols may not raise cholesterol
Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1583 - 1583.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
E. C. Quintao
Reply to KC Hayes
Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1584 - 1584.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.
Agricola
Right arrow Articles by Asakura, L.
Right arrow Articles by Quintão, E. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS